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Be Done? To Whom? When?* 
ADOLPH M. HUTTER, JR., MD, FACC 
Boston, Massachusetts 
In this issue of the Journal, Ellis et al. (1) describe the results 
of primary coronary angioplasty without prior thrombolytic 
therapy performed in the setting of acute myocardial infarc- 
tion. The study patients were classified into 139 patients who 
received angioplasty 6 to 48 h after the onset of chest pain 
(late group) and 117 patients treated with angioplasty within 
6 h of chest pain (early group). All patients underwent 
angioplasty on the basis of clinical evidence of ongoing 
ischemia or hemodynamic compromise. Patients with left 
main coronary artery disease or combination disease of the 
proximal left anterior descending and left circumflex coro- 
nary arteries were excluded, as were patients with lesions 
not suitable for attempted angioplasty. 
The late group had more patients with diabetes mellitus 
(19.4% versus 7.4%, p = 0.003), multivessel disease (61.2% 
versus 48.7%, p = 0.05) and a lower ejection fraction (44% 
versus 49%, p = 0.001). Successful coronary angioplasty 
was accomplished in 78.4% of the late group and 71.8% of 
the early group (hospital mortality rate 13.7% in both 
groups). Successful angioplasty was associated with a 5.5% 
hospital mortality rate, whereas unsuccessful angioplasty 
was associated with a 43.3% hospital mortality rate (p < 
0.001). The predictors of hospital death were cardiogenic 
shock, low ejection fraction, unsuccessful angioplasty and 
older age. The time to angioplasty was not a predictor of 
outcome. The authors conclude that late emergency angio- 
plasty may be justified when the likelihood of angioplasty 
success is very high. 
Assessing the role of coronary angioplasty. This large 
experience of early primary angioplasty in the absence of 
prior thrombolytic therapy is noteworthy and points to the 
difficulty in assessing the role of angioplasty in acute myo- 
cardial infarction. As the authors correctly note, the patients 
*Editorials published in Journd of the American Collqe of Cnrdio/og,v 
reflect the views of the authors and do not necessarily represent the views of 
JACC or the American College of Cardiology. 
From the Cardiac Unit, Department of Medicine, Massachusetts General 
Hospital and Harvard Medical School, Boston, Massachusetts. 
Address for reorints: Adolph M. Hutter. Jr., MD. Ambulatory Care 
Center, Suite 367. Massachusetts General Hospital, Boston, Massachusetts 
02114. 
in this study were selected by the fact that they were 
excluded from the randomized trials assessing thrombolytic 
therapy in acute myocardial infarction underway at the same 
institution. They were also selected by the presence of 
ongoing ischemia or hemodynamic compromise. The early 
and late groups were not comparable because the latter had 
a higher incidence of diabetes, multivessel disease and poor 
left ventricular ejection fraction. There was no control group 
of patients with similar coronary anatomy who received full 
medical therapy, which might include nitrates, beta- 
adrenergic blockers, calcium channel blockers and perhaps 
heparin as individually indicated. Thus, although we know 
that successful angioplasty was associated with a 5.5% 
hospital mortality rate, we do not know what this rate would 
have been in comparable patients with full medical therapy. 
The use of historical controls does not provide a valid point 
of comparison because historical controls are not compara- 
ble. 
One also has to be very careful about comparing the 
results of reperfusion with a drug versus the results of 
reperfusion with a mechanical intervention. The outcome of 
thrombolytic therapy may be related to reperfusion of the 
infarcted artery but may also be influenced by systemic 
effects of the thrombolytic agent, the ability of individual 
thrombolytic agents to prevent reocclusion and perhaps the 
absence of a tendency to further disrupt a thrombogenic 
ulcerative plaque. On the other hand. a mechanical interven- 
tion such as angioplasty has no systemic effects and clearly 
disrupts the occlusive lesion, thereby potentially increasing 
the thrombogenic tendency at the site of angioplasty. It 
would seem. therefore, that full medical therapy, thrombo- 
lytic therapy, angioplasty and coronary bypass surgery 
would have to be compared independently and in combina- 
tion in the setting of acute myocardial infarction. This would 
be difficult, but the point is that we in the medical community 
must be very careful about jumping to conclusions concern- 
ing the efficacy of any one form of therapy in the absence of 
careful prospective randomized trials comparing alternative 
forms of therapy. 
Previous randomized studies. Fortunately, a number of 
such trials are underway and at least partial information is 
being accumulated. Guerci et al. (2) randomized patients 
with acute myocardial infarction to intravenous recombinant 
human tissue plasminogen activator (rt-PA) or placebo and 
then subsequently randomized candidates for angioplasty 
either to undergo angioplasty on the 3rd hospital day or not 
to undergo it during a 10 day study period. Angioplasty was 
successfully carried out in 84% of the patients and was 
associated with a reduction in recurrent episodes of ischemia 
between days 3 and 10 from 19% in those randomly assigned 
not to undergo angioplasty to 5% in those assigned to 
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undergo the procedure (p < 0.05). Angioplasty did not 
influence the at rest ejection fraction on the 10th hospital 
day, but it did improve left ventricular function during a 
submaximal exercise test. The increase in the ejection frac- 
tion during exercise was present among the recipients of 
rt-PA as well as placebo and among patients with a totally 
occluded infarct artery as well as those with subtotal occlu- 
sion of the infarct artery. Thus, a favorable influence was 
noted in the angioplasty group after coronary angioplasty. 
A large cooperative randomized study [Thromholysis and 
Angioplasty in Myocardial Infarction (TAMI)] was reported 
by Topor et al. (3) wherein 150 mg of rt-PA was administered 
to 386 patients with acute myocardial infarction. Seventy- 
five percent of the patients (n = 288) had a patent coronary 
artery at the time of angiography 90 min later. After success- 
ful thrombolysis, 197 patients with a patent but severely 
stenotic vessel suitable for angioplasty were randomly as- 
signed to immediate angioplasty (n = 99) or, if indicated 7 to 
10 days after infarction, to deferred (elective) angioplasty 
(n = 98). The incidence of reocclusion in these two groups 
was similar at 11% in the immediate angioplasty group and 
13% in the elective angioplasty group. Neither group had a 
significant improvement in left ventricular ejection fraction. 
In the elective angioplasty group the rate of crossover to 
emergency angioplasty for recurrent ischemia was 16%, 
whereas 5% of the immediate angioplasty group required 
emergency repeat angioplasty (p = 0.01). On the other hand, 
in 14% of the patients in the elective group, the stenosis was 
substantially reduced by the time of the 7 day follow-up 
angiography, obviating the need for angioplasty. The authors 
appropriately concluded that in patients with initially suc- 
cessful thrombolysis and suitable coronary artery anatomy, 
immediate angioplasty offers no clear advantage over de- 
layed elective angioplasty. 
The same TAMI study group (4) reported in a separate 
article the results of the 96 (25%) of the 386 patients who had 
an occluded infarct artery after rt-PA. Immediate angio- 
plasty was attempted in the infarct-related artery that failed 
to reperfuse with rt-PA unless the vessel was technically 
unsuitable or the infarct was thought to be small. No 
baseline difference could be found between these 96 patients 
and the 288 patients who achieved perfusion with the same 
protocol. Angioplasty achieved reperfusion with ~50% re- 
sidual stenosis in 73% of the 86 patients in whom it was 
attempted whereas 16% were left with a high grade residual 
stenosis and angioplasty failed in 11%. Mortality was 44% in 
those with angioplasty failure, 14% in those left with a high 
residual stenosis and 6% in those with an insignificant 
residual stenosis. In-hospital reocclusion rate, however, was 
29% despite the use of heparin and antiplatelet agents. No 
significant improvement in regional or global left ventricular 
function occurred even in patients with successful angio- 
plasty and persistent vessel patency during the hospitaliza- 
tion. The authors concluded that although angioplasty can 
achieve vessel patency in most patients in whom rt-PA 
therapy fails, the reocclusion rate was high and recovery of 
left ventricular function is minimal. Thus, no significant 
benefit could be demonstrated from angioplasty in that 
group. 
Simoons et al. (5) reported the results of a randomized 
trial of 377 patients with acute myocardial infarction carried 
out by the European Cooperative Study Group for rt-PA. 
These patients were randomized to an invasive strategy 
combining thrombolysis with rt-PA, heparin and aspirin as 
well as immediate coronary angioplasty, compared with a 
“noninvasive strategy” using the same medical treatment 
but without immediate angioplasty. One hundred milligrams 
of rt-PA was used. Angioplasty reduced the percentage 
stenosis in the infarct-related artery, but this was offset by a 
high rate of transient (16%) and sustained (7%) reocclusion 
during the procedure and recurrent ischemia during the first 
24 h (17%). The clinical course was more favorable for the 
noninvasive therapy with a lower incidence of recurrent 
ischemia within 24 h (3%), bleeding complications, hypoten- 
sion and ventricular fibrillation. Mortality rate at 14 days was 
lower in the patients allocated to the noninvasive treatment 
(3%) than in the group allocated to invasive treatment (7%). 
No differences between the treatment groups were observed 
in infarct size or in left ventricular ejection fraction after 10 
to 22 days. The authors concluded that immediate angio- 
plasty does not provide additional benefit and that therefore 
there seemed to be no need for immediate angiography and 
angioplasty in patients with acute myocardial infarction 
treated with rt-PA. 
The Thrombolysis in Myocardial Infarction (TIMI) Re- 
search Group (6) compared immediate angioplasty, when 
appropriate, to angioplasty 18 to 48 hours after acute 
myocardial infarction in patients who received intravenous 
rt-PA therapy. The success rate was 84% in the early group 
and 93% in the late group. No differences between the two 
angioplasty groups were observed for ejection fraction. 
Immediate angioplasty was associated with increased fre- 
quency of bleeding and coronary artery bypass surgery. The 
authors concluded that immediate coronary angiography and 
angioplasty compared with delaying these procedures for 18 
to 48 h provides no advantage and may be harmful. 
Conclusions. Thus, the role of coronary angioplasty in 
acute myocardial infarction remains controversial. The data 
suggest that emergency angioplasty (and perhaps coronary 
angiography) is not indicated in all (most?) patients, offers no 
advantages over late angioplasty and may do harm. Indeed, 
the experience reported by Ellis et al. (1) raises the very 
important question as to whether the attempted angioplasty 
contributed to the high 43.3% hospital mortality rate associ- 
ated with unsuccessful angioplasty. On the other hand, 
patients with ongoing ischemia after myocardial infarction 
should receive appropriate therapy to ty to stop the ishemia 
and prevent infarct extension and death. The type of therapy 

